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Accepted 14 December 2011Fallopian tube cancer is the least common gynecologic
malignancy. The most common histology is high-grade serous
adenocarcinoma. Sarcomas occur infrequently, and malignant
mixed Mu¨llerian tumors (MMMTs) are extremely rare [1].
Because of the rarity of MMMTs of the fallopian tube,
information on optimal management is limited.
A number of studies suggest that cytoreductive surgery
followed by platinum-based chemotherapy may be an effective
treatment, but related data are quite limited [2e7].
Herein, we report a case who responded well after an
optimal debulking operation and postoperative chemotherapy
with paclitaxel and carboplatin. The diagnosis, prognosis, and
treatment are discussed.
The patient was a 53-year-old, gravida 2, para 0, married
Chinese woman with no history of hormone therapy or major
systemic disease. She visited our clinic with the complaint of
postmenopausal vaginal spotting for several months. Bimanual
examination revealed a normal-sized uterus and a left adnexal
mass of about 5 cm in size. Ultrasonography showed a left
adnexal solid tumor measuring 6  4  3 cm3, with prominent
central flow (resistance index was 0.4) (Fig. 1).
Laboratory tests, including a blood cell count, biochem-
istry, tumor marker (CA-125), and chest X-ray, were all within
normal limits. Malignancy was highly suspected; an abdomi-
nopelvic computed tomography (CT) scan revealed a low-
density lesion over the left adnexa (Fig. 2) with a small* Corresponding author. Department of Obstetrics and Gynecology, Tai-
chung Veterans General Hospital, No. 160 Chung-Kang Road, Section 3,
Taichung City, Taiwan.
E-mail address: chlu@vghtc.gov.tw (C.-H. Lu).
1028-4559/$ - see front matter Copyright  2012, Taiwan Association of Obstetri
doi:10.1016/j.tjog.2012.04.025amount of ascites, as well as omental cake. There was no
significant retroperitoneal lymphadenopathy.
The patient then underwent an exploratory laparotomy.
Bilateral ovaries and left fallopian tube were grossly normal.
The right-side tube was swollen like a sausage, about
8  4  4 cm3 in size. On cutting, a solid tumor arising from
the tubal lumen and protruding outside the fimbriae was
observed, which was apparently causing some adhesion to the
posterior uterine wall. Confluent superficial tumor seeding
over the pelvic peritoneum was noted, which was causing
adhesion of the sigmoid colon to the peritoneum. Omental
cake up to 17  3  2 cm3 was noted over the right-side
omentum and low border. There were no enlarged para-
aortic or pelvic lymph nodes. Subdiaphragm and liver
surface were smooth by palpation. The patient underwent
a total hysterectomy, bilateral salpingo-oophorectomy, pelvic
lymph node dissection, para-aortic lymph node sampling,
appendectomy, omentectomy, and maximum resection of
intra-abdominal metastasis. Since there was no gross residual
tumor, the procedure was designated as optimal debulking.
The final pathological diagnosis was MMMT [mixed with
endometrioid adenocarcinoma (50%) and undifferentiated
high grade sarcoma] of the fimbriae (Figs. 3 and 4).
The patient’s stage was assessed as FIGO (Federation of
Gynecology and Obstetrics) stage IIIc. After the first post-
operative week, the patient received six consecutive courses of
chemotherapy, consisting of 175 mg/m2 paclitaxel and AUC 5
carboplatin, administered at 3-week intervals. After the patient
had completed this therapy, we followed up with pelvic
examinations, CA-125 monitoring, periodic pelvic ultrasono-
graphs, chest X-rays, and abdominopelvic CT scans. She iscs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 3. Hematoxylin and eosin stain (200). At the right upper part of the
picture, poorly differentiated carcinoma was composed of highly atypical cells
in a ribbon-like pattern. The undifferentiated sarcoma was predominantly in
the center and lower portion of the picture.
Fig. 1. Ultrasonography. The left adnexa was enlarged due to a tumor with
a sausage-like appearance, approximately 6  4  3 cm3 in size (white arrow).
Prominent central flow was noted.
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surgery and related treatment.
MMMTs, by definition, contain malignant epithelial and
stromal elements. Endometrium is generally reported as the
most common site of mixed Mu¨llerian tumors, whereas the
tube is the least common site [8e10]. MMMTs of the fallo-
pian tube are extremely rare (0.1e0.5% of all gynecologic
malignancies), with fewer than 54 cases reported in the related
literature [11].
Because cancer of the fallopian tube is very uncommon,
a high index of suspicion is necessary for its diagnosis. Most
cases are postmenopausal women with nonspecific abdominal
symptoms of pain or distension and/or vaginal spotting or
bleeding. Usually, the diagnosis is not made until the time of
surgery, with the most common preoperative diagnosis being
ovarian malignancy. Staging procedures at laparotomy should
include collection of ascites or washing cytology, thorough
exploration of all peritoneal surfaces, hysterectomy, bilateral
salpingo-oophorectomy, omentectomy, lymph node sampling,Fig. 2. Computed tomography: axial view. A low-density lesion can be seen at
the left adnexa (white arrow), with a small amount of pelvic ascites.and peritoneal biopsies, as necessary. As with ovarian cancer,
a maximal cytoreductive effort should be emphasized [1]. The
biology of the spreading of tubal cancer seems to resemble
that of ovarian cancer closely, with intra-abdominal peritoneal
surface spread. The most common metastatic sites are the
ovaries, uterus, contralateral tube, and other peritoneal
surfaces; pelvic and para-aortic lymph nodes are not as
frequently involved, and distant metastasis is rare [12].
The prognosis for patients with MMMTs of the fallopian
tube is usually poor. In one review, average survival was only
16.1 months [2]. To date, only three patients, who lived for
more than 5 years without evidence of disease, have been
reported [5]. However, all three of these patients were stage
IA. Some reports in the literature indicate that the prognosis of
MMMTs might be related to the sarcomatous components.
Homologous MMMTs are thought to be associated with
a better prognosis than heterologous MMMTs [5,13,14]. In our
case, the sarcomatous component was undifferentiated, which
was allocated to homologous MMMTs.Fig. 4. IHC stain (200) for cytokeratin AE1/AE3 antibodies. The carcinoma
part is highlighted by the IHC stain for pancytokeratin. The sarcoma part is
negative. IHC ¼ immunohistochemical.
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regarding the best treatment strategies can be reached at this
time. However, surgery is usually followed by postoperative
adjuvant therapy. Platinum-based combination chemotherapy
has been recommended on the basis of its effectiveness against
gynecologic cancer, especially to mixed Mu¨llerian tumors of
the uterus and ovaries [2e7,15].
Studies in the related literature have shown that, for tubal
MMMT, the most frequently used adjuvant chemotherapy is
a combination of cyclophosphamide, doxorubicin, and
cisplatin regimen [2e7]. Data on paclitaxel/platinum combi-
nation chemotherapy in patients with tubal MMMTs are
limited. In one study, a patient with stage IV disease (malig-
nant pleural effusion) underwent complete debulking surgery,
followed by five courses of paclitaxel/platinum combination
chemotherapy. Post-treatment CT showed no evidence of
peritoneal implants. This proved that MMMTs of the fallopian
tube show good response to a paclitaxel/platinum regimen.
However, 8 months after the surgery, the patient was found to
have a recurrent 15  10 cm2 cystic pelvic mass and died with
the disease 12 months after the surgery [4]. Another case
report confirmed that paclitaxel and carboplatin therapy
reduced the size of a measurable tumor in a patient with
MMMT of the fallopian tube effectively (shrunk by 60% after
three courses of chemotherapy). This patient was classified as
FIGO stage IIIc, and was alive/free of disease 28 months after
the debulking surgery [16]. Our patient was also in stage IIIc.
She has prolonged survival after an optimal debulking oper-
ation and six courses of paclitaxel/carboplatin combination
chemotherapy. Our patient remains disease free after 5 years
of regular follow-up at our outpatient department. To the best
of our knowledge, she is the longest-surviving patient with
advanced stage (stage IIIeIV) MMMT, as documented in the
literature.
Although data about the best treatment strategies for
MMMT are limited, our patient’s excellent response to
paclitaxel/platinum chemotherapy indicates that this regimen
may be effective for the treatment of MMMT of the fallopian
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